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Abstract
Myotonic dystrophy type 1 (DM1) is a severe neuromuscular disorder caused by the expres-
sion of trinucleotide repeat-containing DMPK transcripts. Abnormally expanded (CUG)n
repeats in these transcripts form hairpin-like structures that cause the RNA to accumulate in
the cell nucleus by sequestering isoforms of the Muscleblind (MBNL) family, tissue-specific
regulators of developmentally programmed, post-transcriptional processes in RNA metabo-
lism. Through this mechanism, the function of MBNL in RNA processing becomes domi-
nantly perturbed, which eventually leads to aberrant alternative splicing and the expression
of foetal splice variants of a wide variety of proteins, including the MBNL isoforms them-
selves. Here, we employ a patient-derived muscle cell model for DM1 to examine in detail
the expression of MBNL RNA and protein variants during myogenic differentiation. This
DM1 model consists of a panel of isogenic myoblast cell lines that either contain a patho-
genic DMPK allele with a congenital mutation of 2600 triplets, or lack this expanded repeat
through CRISPR/Cas9-mediated gene editing. We found that the temporal expression lev-
els of MBNL1, MBNL2 and MBNL3 RNAs are not influenced by presence of the (CTG)2600
repeat during myogenesis in vitro. However, throughout myoblast proliferation and differen-
tiation to myotubes a disproportionate inclusion of MBNL1 exon 5 and MBNL2 exons 5 and
8 occurs in cells with the (CTG)2600 repeat. As a consequence, a reduced quantity and
imbalanced collection of splice variants of MBNL1 and MBNL2 accumulates in both the cyto-
plasm and the nucleus of DM1 myoblasts and myotubes. We thus propose that both the
quantitative and qualitative changes in the intracellular partitioning of MBNL proteins are a
pivotal cause of skeletal muscle problems in DM1, starting already in muscle progenitor
cells.
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Introduction
Members of the Muscleblind-like (MBNL) protein family belong to a class of tissue-specific,
developmentally programmed regulators of gene expression [1,2]. They control many aspects
of RNA metabolism, such as alternative splicing and alternative polyadenylation, mRNA local-
ization, translation and stability, and microRNA processing. In humans, like in other mam-
mals, three MBNL isoforms, MBNL1, MBNL2 and MBNL3 are expressed. MBNL1 and MBNL2
are found ubiquitously, with MBNL1 being more prominent in skeletal muscle and MBNL2
relatively abundant in brain [3–5]. Expression of MBNL3 is generally low in all tissues, with
exception of liver and placenta [2,3,5,6].
MBNL1-3 are highly homologous genes, of which the open reading frames are distributed
over 9–10 exons, many of which are alternatively spliced [1,2]. Especially splicing of exons in
the 3’ end of the primary MBNL transcripts is cell-type- and tissue-specific, and under devel-
opmental control [2,7–14]. Various combinations of exon inclusion and skipping events give
rise to the production of a complex set of MBNL protein variants with different functional
characteristics [1,2]. This process has been studied in detail predominantly for MBNL1. More
specifically, inclusion of exon 5 (54 nts; nomenclature taken from Pascual et al. [1]) enhances
nuclear localization of MBNL1, presence of exon 7 (36 nts) results in increased MBNL1 dimer-
ization, while exon 3 (204 nts), almost always included, regulates MBNL1 RNA binding and
splicing activities [8,10,11,13–16].
Aberrant alternative splicing of MBNL1 and MBNL2 is characteristic of the foetal splice pat-
tern reported in patients with the severe neuromuscular disease myotonic dystrophy type 1
(DM1; OMIM#160900). In fact, functional down-regulation of MBNL isoforms is thought to
be the actual cause of the pathological adult-to-foetal splice switch typical for this disease [2].
DM1 patients are characterized by the expression of an expanded (CTG)n repeat in the 3’
untranslated region of DMPK [17]. In unaffected individuals, the number of triplets in this
gene varies between 5 and 37, but in patients with DM1 the repeat can expand to several thou-
sand repeat units. Consequently, in tissues where the DMPK gene is expressed long pathologi-
cal DMPK transcripts are formed. These RNAs remain retained in the cell nucleus where they
form long hairpin structures that aberrantly sequester MBNL protein. This sequestration is
associated with the formation of DMPK (CUG)n RNA-MBNL aggregates, which can be visual-
ized as so-called foci by microscopy [18]. Also other effects on the intracellular partitioning of
MBNL protein may occur. In turn, these processes may have widespread effects on muscle
integrity and functioning, typical for the problems seen in DM1 patients. For example, reduced
MBNL1 expression in proliferating DM1 myoblasts impairs foci formation, whereas enhanced
MBNL1 expression induces nuclear retention of (CUG)n-expanded transcripts [13,19]. More-
over, Mbnl knockout mouse models replicate splicing abnormalities and disease symptoms of
patients with DM1 [3,4,6,20–22].
All in all, there is overwhelming evidence that the MBNL gene family plays a crucial role in
the muscle phenotype in DM1. Unfortunately, we still know remarkably little about the tempo-
ral effects of presence of an expanded (CTG)n repeat on the expression of MBNL family mem-
bers during skeletal muscle myogenesis. We therefore present here a detailed study on RNA
and protein expression, alternative splice modes and subcellular localization of MBNL iso-
forms in proliferating and differentiating cells of a human muscle cell model for DM1. This
unique cell panel includes isogenic control myoblasts from which the expanded (CTG)2600
mutation has been excised via CRISPR/Cas9-mediated gene editing [23]. We found that RNA
expression levels of MBNL1, MBNL2 and MBNL3 were similar in cells with and without the
expanded repeat and did not noticeably change during myogenesis. However, at the post-tran-
scriptional level, presence of the (CTG)2600 repeat caused a significant shift in alternative
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splicing of both MBNL1 and MBNL2 primary transcripts. At the post-translational level, this
RNA splicing imbalance resulted in lower intracellular concentrations and also altered splice
variant compositions of the MBNL1 and MBNL2 protein populations. These changes were
already apparent in muscle precursor cells, the proliferating myoblasts, and were accompanied
by a sustained, reduction of MBNL protein during differentiation to myotubes. Our study thus
demonstrates a disturbed MBNL expression in DM1 pathology, already early during myogen-
esis, before myotube formation.
Materials and methods
Cell culture
Immortalized human DM1 myoblasts (named DM11) carrying DMPK alleles with (CTG)13
and (CTG)2600 repeats and CRISPR/Cas9-edited isogenic clones lacking both repeats as
described [23] were used in this study. These myoblasts were propagated in a 1:1 mix of Skele-
tal Muscle Cell Growth Medium (PromoCell, Heidelberg, Germany) and F-10 Nutrient mix
(Gibco, Carlsbad, CA, USA), supplemented with 15% (v/v) Hyclone foetal bovine serum (GE
Healthcare Life Sciences, Chalfont St. Giles, UK) and 1% glutamax (Gibco), on culture dishes
coated with 0.1% gelatin (Sigma-Aldrich, St. Louis, MO, USA), at 7.5% CO2 and 37˚C. Myo-
genic differentiation to myotubes was induced by growing the myoblasts to confluency and
replacing the proliferation medium by differentiation medium consisting of DMEM supple-
mented with 1% glutamax, 10 μg/mL insulin (Sigma-Aldrich) and 100 μg/mL apo-transferrin
(Sigma-Aldrich). These low-serum conditions were maintained for up to five days. Culture
medium was changed every other day.
RNA isolation, RT-PCR and RT-qPCR
RNA was isolated using the Aurum Total RNA Mini Kit (Bio-Rad, Hercules, CA). RNA yield
and purity were verified by absorbance at 260/280 nm (NanoVUE spectrophotometer, GE
Healthcare Life Sciences). RNA was reverse transcribed using the iScript cDNA Synthesis Kit
(Bio-Rad). To measure MBNL1 and MBNL2 splice variants, semi-quantitative PCR was per-
formed using Q5 High-Fidelity DNA Polymerase (NEB) and the primers listed in S1 Table.
The PCR program involved initial denaturation at 98˚C for 3 min, followed by 30 cycles at
98˚C for 10 seconds, 69˚C (MBNL1) or 72˚C (MBNL2) for 30 seconds and 72˚C for 30 sec-
onds, and a final extension at 72˚C for 10 minutes. PCR products were analysed on the QIAx-
cel Advanced capillary electrophoresis system (QIAGEN, Venlo, Netherlands) using the DNA
High Resolution Kit, along with the 15–600 bp alignment marker and 25–500 bp size marker.
QIAxcel ScreenGel Software (1.5.0.16; QIAGEN) was used to quantify the various splice
products.
For quantitative RT-PCR (RT-qPCR), 3 μL ten-fold diluted cDNA preparation was mixed
in a final volume of 10 μL containing 5 μL iQ SYBR Green Supermix (Bio-Rad) and 4 pmol of
each primer (S1 Table). Samples were analysed using a CFX96 Real-time System (Bio-Rad). A
melting curve was obtained for each sample in order to confirm single product amplification.
cDNA samples from no template control (NTC) and no reverse transcriptase control (NRT)
were included as negative controls. GAPDH and HPRT1 were used as reference genes.
RNA sequencing and analysis
RNA was isolated as described from proliferating myoblasts growing at 80% confluency. RNA-
sequencing (RNA-seq) libraries were prepared using the Unstranded TruSeq mRNA kit (Illu-
mina, San Diego, CA, USA) and ~40 million 100-bp paired end reads were obtained using the
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Hiseq4000 platform (Illumina), all performed by the Beijing Genomics Institute (BGI, Hong
Kong). Clean reads were mapped to the hG38 genome assembly using HISAT v0.1.6-beta [24]
and transcripts were reconstructed using StringTie v1.0.4 [25]. Integrative Genomics Viewer
[26] was used in conjunction with rMATS v3.0.9 [27] for quantification of differential splicing.
For quantification of total expression levels RSEM v1.2.12 [28] was used after merging reads
for transcripts with an identical reference transcript with BowTie2 v2.2.5 [29]. To compare
expression levels of different genes FPKM values were used. Raw RNA-seq data and down-
stream analyses were deposited in the Gene Expression Omnibus under the accession number
GSE127296.
Immunofluorescence assay
Myoblasts were cultured on 0.1% gelatin-coated coverslips and fixed the next day. For myo-
tube cultures, myoblasts were cultured in 0.1% gelatin-coated IBIDI 8-wells (IBIDI) and fixed
the next day or after five days of differentiation in 2% PFA in 0.1 M phosphate buffer, pH 7.4.
After fixation, cells were washed three times with PBS and permeabilized with an acetone
methanol mixture (1:1 w/v). Cells were incubated in 3% bovine serum albumin (BSA) (w/v)
(Sigma-Aldrich) in PBS for 30 min at room temperature. After overnight incubation at 4˚C
with primary antibodies (S2 Table) diluted in 3% BSA in PBS, the samples were washed three
times with PBS and incubated with goat-anti-mouse AF488 (Thermo Fisher Scientific, Boston,
MA, USA) and 100 ng/mL DAPI (Sigma-Aldrich) in blocking buffer (3% BSA and 0.1% (w/v)
glycine in PBS) for one hour at room temperature. After three PBS washes, samples were
stored in PBS at 4˚C until imaging. Myoblast samples were imaged using a Leica DMI6000B
high-content microscope with a 63x objective. Per coverslip, at least 30 cells were examined
using the same acquisition time. Myotube samples were imaged using a Zeiss LSM880 micro-
scope (Plan-Apochromat 20x N/A 0.8). Analysis of the signal was performed with FIJI software
using the same size region of interest (ROI), randomly placed in the nucleus or cytosol of a
myotube or myoblast, using the DAPI signal as mask for the nucleus.
Protein extraction, SDS-polyacrylamide gel electrophoresis and western
blotting
After two PBS washes, whole cells were lysed in 2x Laemmli sample buffer, followed by boiling
for 5 minutes at 95˚C. Resulting protein mixtures, along with ProSieve Quadcolor protein
marker (Lonza), were electrophoresed on 10% SDS polyacrylamide gels in SDS running buffer.
Proteins were transferred to Immobilin PVDF membrane (GE healthcare, 0.45 μm pore size)
and membranes were blocked for one hour with 3% BSA in PBS with 0.1% Tween-20 (PBST)
and incubated with primary antibodies (S2 Table) diluted in blocking buffer overnight at 4˚C.
Membranes were washed three times in PBST and incubated with appropriate IRDeye second-
ary antibody (IRDeye 800 CW goat anti-rabbit or IRDeye 680 LT goat anti-mouse; LI-COR
Biosciences, Lincoln, NE, USA) in PBST for one hour and washed three times before being
scanned in 700 nm and 800 nm wavelength channels on the Odyssey Clx imaging system
(LI-COR Biosciences). Densitometry was performed using Image studio version 5.0 software
(LI-COR Biosciences).
Subcellular fractionation
For subcellular fractionation, myoblasts were grown to 80% confluence, collected by trypsini-
sation and pelleted by centrifugation at 1,000xg for 5 min at 4˚C. Pellets were washed twice
with ice-cold PBS. The cell pellets were resuspended in ice-cold cell disruption buffer, 10 mM
KCl, 1.5 mM MgCl2, 20 mM Tris-Cl (pH 7.5), 1 mM DTT [30], and incubated on ice for 10
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minutes. Cells were lysed by membrane disruption in a chilled Dounce homogenizer (tight
pestle, 0.025–0.076 mm; Wheaton for 15 strokes) after which Triton X-100 was added to a
final concentration of 0.1%. The lysate was spun at 1,500xg for 5 min at 4˚C. The supernatant
(cytoplasmic fraction) and the pellet (nuclear fraction) were each diluted in 2x Laemmli sam-
ple buffer for later use in SDS-PAGE. Enrichment for cytoplasmic and nuclear content was
verified by western blotting using E7 tubulin and lamin A/C antibodies (S2 Table). For subcel-
lular fractionation of myotubes, five-day differentiated myotube cultures were used. To sepa-
rate multinucleated myotubes from mononuclear cells still present in the culture, myotubes
were selectively released from the substrate by mild trypsinization at room temperature for 2
minutes. The myotube-enriched cell population was fractionated and analyzed as described
for myoblasts except that the cell pellet was incubated in cell disruption buffer for 5 minutes
and 20 strokes were used.
Statistical analysis
All experiments were performed in triplicate unless otherwise specified and representative
results are shown. Statistical analysis was performed using Prism software (4.01; GraphPad,
LaJolla, CA), using two-way ANOVA with α = 0.05. � p<0.05, �� p<0.01, and ��� p<0.001.
Error bars indicate standard errors of the mean (SEM).
Results
MBNL1, MBNL2 and MBNL3 RNA levels are unchanged after excision of
the (CTG)2600 repeat
To study RNA and protein expression of MBNL isoforms during myogenesis in DM1, we used
the myoblast cell panel previously generated via gene editing in our lab (Fig 1A) [23]. The
parental myoblast cell line from which the cell panel was derived carried 13 and 2600 CTG
triplets in its two DMPK alleles [31]. Following the CRISPR/Cas9 editing procedure and care-
ful cell cloning, we obtained four myoblast lines from which the mutant repeat was removed
and four lines still carrying the (CTG)2600 repeat expansion (one of which being the parental
cell line). Three of the four lines in the former group contained DMPK alleles lacking both the
expanded and the normal repeat tract (the so-called ΔΔ lines), while one line still carried an
unmodified (CTG)13 allele (line 13/Δ) [23]. This myoblast cell panel provides an elegant, iso-
genic study model to analyse effects of presence of a congenital DM1 repeat on endogenous
MBNL expression.
First, to quantify MBNL expression, we performed RNA-seq analysis on proliferating
myoblasts. Transcript levels of MBNL1, MBNL2 and MBNL3 in (CTG)2600 repeat-contain-
ing cells did not differ from those in cells from which the repeat expansion was removed
(Fig 1B). When comparing the expression of the three individual MBNL isoforms, we
found that MBNL2 RNA abundance was around three times lower than that of MBNL1.
MBNL3 RNA was even much lower expressed, in fact around 250 times lower than MBNL1
[32].
RT-qPCR analysis showed that MBNL expression was largely unresponsive to five days of
myogenic differentiation in vitro (Fig 1C–1E). RNA abundance of all three genes in proliferat-
ing myoblasts (day -2), aligned myoblasts committed to cell fusion (day 0), and in differentiat-
ing myotube cultures (day 5) was similar between cell lines with and without (CTG)2600
repeat. This analysis further confirmed that expression of MBNL1 and MBNL2 was much
higher than MBNL3. We decided to concentrate this study on MBNL1 and MBNL2, the two
most prominent MBNL isoforms in myogenic progenitor cells.
Dysregulation of MBNL expression in DM1
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Excessive exon inclusion of MBNL1 exon 5 and MBNL2 exons 5 and 8
occurs in cells with a (CTG)2600 repeat
Alternative splicing of MBNL1 and MBNL2 pre-mRNAs results in the production of a complex
mix of at least a dozen possible splice variants for each isoform (see Fig 2A–2D for the MBNL1
and MBNL2 exon nomenclature used in this paper [1,8,9,12,14]. In adult DM1 muscle, abnor-
mal inclusion of MBNL1 exon 5 (54 nts) is an accepted hallmark for the foetal splice pattern
characteristic for the disease [8,9,12]. Abnormal splicing of MBNL2 in DM1 has not been stud-
ied in detail yet, but it has been reported that also for this isoform the conserved exon 5 (54
nts) is overrepresented in mature transcripts [8,10].
We have analysed MBNL1 and MBNL2 splicing in proliferating myoblasts using RNA-seq
and focussed on the main alternatively spliced regions, encompassing MBNL1 exons 5–9 and
MBNL2 exons 5–8 (Fig 2A–2D) [1,14]. For MBNL1, we identified manifest alternative use of
exons 5, 7 and 8, while exons 6 and 9 were nearly always constitutively included and excluded,
respectively. In the case of MBNL2, exons 5 and 8 were alternatively spliced, while exons 6 and
7 were nearly always included and excluded, respectively. Exons 1–4, including alternative
exon 3, were present in essentially all MBNL1 and MBNL2 transcripts in the samples
examined.
When comparing myoblasts carrying the (CTG)2600 repeat with cells from which the
repeat had been recently removed, we found that MBNL1 exon 5 was preferentially included
in cells with the repeat (56% vs 24%; p<0.001; FDR = 0.0001) (Fig 2E). No significant differ-
ences were seen for MBNL1 exon 7 (64% vs 61%) nor exon 8 (94% vs 91%). For MBNL2, we
Fig 1. RNA expression of MBNL isoforms in myogenic cell cultures with and without expanded (CTG)2600 repeat. (A)
Schematic outline of the CRISPR/Cas9 editing procedure by which the (CTG)2600 repeat was excised from the DMPK gene in the
DM1 myoblast cell line named DM11 [23]. As a result, a panel of eight isogenic myoblast cell lines was obtained: four non-edited
clonal cell lines with expanded (CTG)2600 repeat (the parental cell line and three independent clones) and four clonal lines from
which the mutant repeat was removed. (B) MBNL1, MBNL2 and MBNL3 expression in proliferating myoblasts determined by RNA-
seq. (C-E) Quantification of MBNL1, MBNL2 and MBNL3 RNA levels in proliferating myoblasts (day -2) and day 0 or 5 of myogenic
differentiation measured by RT-qPCR. All bars show the mean values for the four cell lines with and without (CTG)2600 repeat
expansion, all values are relative to the parental cell line.
https://doi.org/10.1371/journal.pone.0217317.g001
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measured increased inclusion of exon 5 (26% vs 6%; p<0.001; FDR = 0.007) and exon 8 (87%
vs 63%; p<0.001; FDR = 0.0005) in myoblasts with a (CTG)2600 repeat (Fig 2F).
We subsequently performed semi-quantitative RT-PCR across MBNL exons 5 to 9/8 on
RNA isolated from proliferating and differentiating myoblasts to verify the RNA-seq data and
to investigate the combinatorial use of multiple alternative splice events during myogenesis.
We could confirm that in proliferating myoblasts containing the (CTG)2600 expansion the
majority of MBNL1 transcripts included exon 5, unlike in myoblasts without the expanded
Fig 2. Alternative splicing of MBNL1 and MBNL2 during myogenic differentiation in vitro in presence and absence of an
expanded (CTG)2600 repeat. (A, B) Gene structures of MBNL1 and MBNL2, adapted from [1,11]. Boxes represent exons,
numbered 1–10, connected by horizontal lines, the introns. Exon lengths are indicated in base pairs. Primers for RT-PCR are
shown as red arrows. (C, D) The main alternative splice modes for MBNL1 and MBNL2 identified in this study and the molecular
weights of the corresponding protein products, adapted from [1,11]. (E, F) Summary of RNA-seq data of the most prominent
alternative splice modes of MBNL1 and MBNL2 in proliferating myoblasts with and without (CTG)2600 repeat (averaged data of
four cell lines for each condition). Numerals indicate the percentage of reads spanning an upstream exon to a downstream exon. (G,
H) Representative QIAxcel images of RT-PCR analyses of the exon 4 to exon 10/9 region in MBNL1 and MBNL2, respectively, in
proliferating myoblasts (-2) and at day 0 and 5 of myogenic differentiation. (I, J) Quantification of the RT-PCR data shown in (G, H).
https://doi.org/10.1371/journal.pone.0217317.g002
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repeat (75% vs 8%; Fig 2G and 2I). We assume that the slightly deviating ratios obtained by
RT-PCR and RNA-seq analysis are due to fundamental technical dissimilarities between the
two methods. Inclusion of MBNL1 exon 7 was indeed independent of expanded repeat pres-
ence (80% vs 75%). When we looked more specifically at combinatorial use of exons 5 and 7,
we found that the +ex5+ex7 and +ex5-ex7 MBNL1 variants, encoding MBNL143 and
MBNL142 proteins respectively, were around nine-fold higher expressed in cells carrying an
expanded repeat than in cells without repeat. In contrast, the -ex5+ex7 and -ex5-ex7 variants,
corresponding to the smaller MBNL141 and MBNL140 proteins respectively, were four-fold
less abundant in cells with repeat. Of note, despite the fact that alternative splicing and myo-
genesis are intrinsically related processes, the MBNL1 splice pattern did not undergo an overt
change upon the onset of differentiation or the next five days of further myoblast-to-myotube
differentiation in vitro, irrespective of repeat presence.
RT-PCR analysis of the MBNL2 splice pattern confirmed that proliferating myoblasts con-
taining the (CTG)2600 expansion showed a higher degree of exon 5 and exon 8 inclusion than
those without (25% vs 7%, and 74% vs 36%, respectively) (Fig 2H and 2J). We observed that
the +ex5+ex8 and -ex5+ex8 MBNL2 mRNA variants, encoding MBNL240 and MBNL238 pro-
teins respectively, were both around two-fold higher expressed, whereas the -ex5-ex8 variant,
encoding MBNL239 protein was around three-fold reduced in (CTG)2600 containing myo-
blasts. The +ex5-ex8 mRNA variant, encoding MBNL241 protein, could barely be detected at
all. Remarkably, MBNL2 exon 5 and exon 8 inclusion increased significantly during myogenic
differentiation, but only in cells with the (CTG)2600 repeat. This phenomenon seems a distinct
feature of MBNL2 expression, as it was not observed for MBNL1.
All data combined, we conclude that alternative MBNL splicing is noticeably perturbed dur-
ing the proliferative phase of DM1 myoblast cell formation and involves increased inclusion of
MBNL1 exon 5 and MBNL2 exons 5 and 8. Upon induction of myogenic differentiation, this
situation is maintained during the subsequent phase of quiescence and myoblast fusion into
Fig 3. MBNL1 and MBNL2 expression in proliferating and differentiating myogenic cells with and without (CTG)2600 repeat.
(A,B) Representative western blots for MBNL1 and MBNL2 from cell lines with (4F9-13/2600) and without (4A3-ΔΔ) the (CTG)
2600 repeat. (C,D) Quantification of MBNL1 and MBNL2 expression, including specific variants, in arbitrary units (a.u.) after
normalization to β-tubulin expression. Bars summarize data from two cell lines with and two cell lines without (CTG)2600 repeat.
Each cell line was measured three times, in independent experiments.
https://doi.org/10.1371/journal.pone.0217317.g003
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myotubes, whereby a specific transition occurred between MBNL2 +ex5+ex8 (MBNL240) and
-ex5+ex8 (MBNL238) variants.
(CTG)2600 repeat-induced alternative splicing results in reduced MBNL1
and MBNL2 levels and altered protein composition
We next examined whether the abnormally spliced, yet similar total levels of MBNL1 and
MBNL2 mRNAs would significantly alter MBNL protein expression in cells with a CTG(2600)
repeat compared to cells lacking the repeat. To this end, whole-cell protein lysates of proliferat-
ing myoblast cultures and of cultures harvested at different time points after initiation of dif-
ferentiation were prepared and used in western blotting. The MBNL1 antibody MB1a that we
used for detection was directed against an epitope encoded by exon 3 [33], present in essen-
tially all MBNL1 variants in our cells.
From the inferred amino acid (aa) sequences, we predicted that exon 5 or exon 7 inclusion
would contribute an extra 2.0 kDa (18 aa) or 1.2 kDa (12 aa), respectively to the total molecular
weight of the MBNL1 variants. The blots showed a complex collection of MBNL1 signals with
migration behaviour around the 40 kDa marker protein, as expected (Fig 3A). Two bands
were most prominent, irrespective of the presence of an expanded repeat in the cells. Taking
our RT-PCR results and the available literature data [11,12,33] into account, we assumed
that the top signal represented mainly MBNL143 (+ex5+ex7) cosegregating with MNL142
(+ex5-ex7), while in the bottom signal MBNL141 (-ex5+ex7) and MBNL140 (-ex5-ex7)
migrated together. Total MBNL1 levels were three to four-fold lower in proliferating myoblasts
with a (CTG)2600 repeat than in cells without the repeat (Fig 3C). This difference in expres-
sion was mainly caused by a reduction in the MBNL140/41 (-ex5±ex7) variants (bottom signal),
the dominant proteins in cells lacking the repeat (approximately 75% of total MBNL1). More
specifically, during five days of differentiation, the total MBNL1 level, again mainly the
MBNL140/41 variants, decreased around two-fold, particularly in cultures with a (CTG)2600
repeat.
Also for MBNL2, multiple signals were detected, using antibody MB2A directed at the N-
terminus shared by all MBNL2 variants [33] (Fig 3B). Inclusion of exon 5 would contribute an
extra 2.0 kDa (18 aa) to MBNL2, while exon 8 inclusion initiates a shift in the open reading
frame resulting in a novel C-terminus and a reduction in molecular weight of 1.2 kDa. The top
signal, most prominently observed in cells with the (CTG)2600 repeat probably reflected
MBNL240 (+ex5+ex8), cosegregating with MBNL241 from the barely expressed +ex5-ex8 splice
variant. We assumed that the bottom signal represented a mix of MBNL239 (-ex5-ex8) and
MBNL238 (-ex5+ex8). Total MBNL2 levels were not significantly lower in cells with a (CTG)
2600 repeat than in cells without the repeat (Fig 3D). However, in cells containing the (CTG)
2600 repeat, the MBNL240/41 (+ex5±ex8) variants were significantly more abundant under dif-
ferentiation conditions; in fact, these MBNL2 variants were essentially absent in cells from
which the repeat expansion had been removed. In contrast to MBNL1, total MBNL2 level
remained relatively constant during myogenic differentiation.
In sum, the total level and protein composition of both MBNL1 and MBNL2 is altered in
the presence of the expanded (CTG)2600 repeat. During myogenic differentiation, MBNL1,
but not MBNL2, levels decreased slightly, particularly in cells with the repeat.
MBNL1 and MBNL2 are reduced in the nucleus and in the cytoplasm in
DM1 myoblasts and myotubes
We wondered about the effects of lower protein expression and altered protein composition
on MBNL localization in the cell. It has been reported that inclusion of MBNL1 exon 5 is
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implicated in the nuclear localization of MBNL1 [10,11,13]. Moreover, the exon 5-encoded
amino acid stretch is highly conserved in MBNL2. We employed immunofluorescent micros-
copy using the same antibodies as for western blotting, and examined the subcellular distribu-
tion of MBNL1 and MBNL2 in myoblasts with and without (CTG)2600 repeat.
The typical DM1 foci in the nuclei of cells with the expanded (CTG)n repeat contained
MBNL1 as well as MBNL2 (Fig 4A and 4B; on average around 3 foci per nucleus). Notably,
only a fraction of MBNL1 and MBNL2 was contained within these foci and these typical
intense signals were not present in cells lacking the repeat [23]. In fact, we always observed a
diffuse, homogenous distribution of MBNL1 and MBNL2 in both the cytoplasm and the
nucleus. Careful quantification of MBNL1 staining in individual cells through advanced image
analysis showed that the average MBNL protein content was three to four-fold higher in the
nucleus than in the cytoplasm in all cell lines (Fig 4C and 4D). Notably, up to five-fold differ-
ences in intensity were measured between cells of one clonal population, illustrating a high
cell-to-cell variability. More importantly, when comparing the staining intensities between the
two cell populations, we consistently measured a two to three-fold higher MBNL1 intensity in
both compartments in cells lacking the (CTG)2600 repeat (Fig 4C and 4D). In contrast,
MBNL2 staining intensities were essentially equal in the nucleus and the cytoplasm, while only
some clones without the (CTG)2600 repeat displayed a significantly higher expression in both
cellular compartments than cell lines with the expanded repeat (Fig 4E and 4F).
Since immunofluorescence detection in situ using antibodies MB1a and MB2a did not
allow for discrimination between MBNL variants, we performed subcellular fractionation of
proliferating myoblasts followed by western blotting to identify the MBNL1 and MBNL2 vari-
ants in the cytoplasmic and nuclear-enriched fractions. As expected, the MBNL142/43 and
MBNL240/41 variants, corresponding to exon 5 inclusion, were enriched in the nuclear frac-
tions, particularly in cells with the expanded (CTG)2600 repeat (S1A and S1B Fig).
The subcellular localization of MBNL was also determined in five-day old multinucleated
myotubes. For both MBNL1 and MBNL2, next to the nuclear foci in (CTG)2600 repeat-con-
taining cells, we observed a diffuse granular staining in the nucleus and in the cytoplasm (Fig
5A–5D). Excision of the (CTG)2600 repeat resulted in a two to three-fold higher MBNL1
intensity in the nuclear and cytoplasmic compartment, respectively, and a 1.5-fold higher
MBNL2 intensity in both compartments (Fig 5E–5H). More importantly, in contrast to the
localization in myoblasts, we measured on average in myotubes an essentially equal distribu-
tion of MBNL1 and MBNL2 throughout the cell, irrespective of repeat presence. It should be
noted however, that we regularly observed myotubes containing nuclei with highly variable
MBNL1 and MBNL2 intensities. Subcellular fractionation followed by western blotting con-
firmed that also in myotubes MBNL142/43 and MBNL240/41 variants were more abundant in
the nuclear fractions, particularly in cells with the expanded (CTG)2600 repeat (S1C and
S1D Fig).
Discussion
As important cell type-specific regulators of RNA processing, MBNL family members must be
spatiotemporally expressed with high accuracy during development. Functional loss or change
in the composition of the cellular MBNL isoform population is thought to be, at least in part,
responsible for the spliceopathy typically seen in DM1 [34]. In the present study, we examined
MBNL expression, with a focus on MBNL1 and MBNL2, in a well-controlled human cell
model for DM1 with normal expression of an expanded repeat. Our unique isogenic muscle
cell panel, comprising several independent cell lines with and without a congenital DM-type
mutation, enabled us to study repeat effects without possible confounding influences of genetic
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Fig 4. Subcellular localization of MBNL1 and MBNL2 in myoblasts with and without (CTG)2600 repeat. (A, B)
Immunofluorescent localization of MBNL1 and MBNL2 in proliferating myoblasts with (4F9) and without (4A3) the (CTG)2600
repeat expansion. Merged images show DAPI in blue, MBNL1 in green and MBNL2 in magenta. Scale bars are 50 μm. (C-F)
Quantification of MBNL1 and MBNL2 levels in the nucleus and the cytoplasm in all eight cell lines. Each symbol represents the
average intensity in one myoblast.
https://doi.org/10.1371/journal.pone.0217317.g004
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background or other forms of interpatient variability. Using independent methods for the
identification and quantification of RNA and protein, we investigated MBNL expression in
detail in proliferating myoblasts and in differentiating myotubes. Earlier, we and others had
already shown that (CTG)n repeat excision in DM1 cells restores the normal cellular pheno-
type [23,35,36]. With regard to the progressive muscle phenotype in DM1, we conclude here
that (CTG)n-repeat toxicity perturbs MBNL expression as early as in myoblasts, the muscle
progenitor cells.
RNA-seq and RT-PCR analyses demonstrated that removal of the (CTG)2600 repeat did
not alter RNA expression levels of any of the three MBNL isoforms in our cell model. This
observation matches findings from a comparative RT-qPCR study on muscle biopsies from a
cohort of DM1 patients and unaffected individuals [37] and a recent large transcriptomics
Fig 5. Subcellular distribution of MBNL1 and MBNL2 in five-day differentiated myotubes with and without (CTG)2600 repeat.
(A-D) Immunofluorescent localization of MBNL1 and MBNL2 in myotubes with (4F9) and without (4A3) the (CTG)2600 repeat
expansion, after five days in differentiation medium. Images show DAPI in blue, MBNL1 in green and MBNL2 in magenta. Bars are
50 μm in large images and 10 μm in insets. (E-H) Quantification of MBNL1 and MBNL2 levels in the nucleus and the cytoplasm in
all eight cell lines. Each symbol represents the average intensity in one multinucleated myotube.
https://doi.org/10.1371/journal.pone.0217317.g005
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study on quadriceps samples from patients and controls [38]. Interestingly, the latter study
reported a slight increase in MBNL1 expression, but not MBNL2 and MBNL3, in tibialis mus-
cle from DM1 patients compared to controls, indicating that expression levels can vary in dif-
ferent muscle tissues [38]. We also observed that MBNL RNA levels did not overtly change
during myoblast alignment and myotube formation during five days in vitro. All in all, these
RNA quantifications indicate that changes in MBNL protein expression in early myogenesis in
DM1 must be predominantly the result of (CTG)n repeat-mediated effects at the posttran-
scriptional level.
Probably the main level of posttranscriptional regulation of MBNL is alternative splicing.
Alternative splicing of MBNL1 and, to a limited extent, MBNL2 has been studied by a number
of laboratories, but only rarely under well-controlled conditions of normal expression of an
expanded DM1 repeat [2,7–14]. The current literature is confusing with regard to MBNL gene
structure, but using the nomenclature summarized in Fig 2 [1], we could confirm alternative
splicing of MBNL1 exons 3 (204 nts), 5 (54 nts), 7 (36 nts) and 8 (95 nts) in muscle cells. Of
these, we basically only found a significant increase of exon 5 inclusion in DM1 cells. We did
not detect increased inclusion of exon 7, which was reported in DM1 brain [9]. The two alter-
natively spliced MBNL2 exons, exon 5 (54 nts) and exon 8 (95 nts), were both preferentially
included in DM1 cells. It is important to note that we mainly detected a shift in splice variant
composition of MBNL1 and MBNL2 and did not identify significant expression of uncommon
or novel splice variants.
When comparing the data on RNA and protein expression from either cells with or without
(CTG)2600 repeat, we did not observe a quantitative one-to-one correlation between alter-
ations in MBNL mRNA and protein splice variant composition, indicating additional regula-
tory mechanisms after the MBNL mRNA has been made. The most likely explanation for the
difference in the regulation of MBNL mRNA and protein abundance are variations in mRNA
translation efficiency and protein stability [39,40]. The latter may be related to differences in
multimerization behaviour and subcellular localization between splice variants. Detailed anal-
ysis of MBNL splice variant synthesis rate and half-life, which is beyond the scope of this
paper, is needed to clarify this issue.
We found that MBNL1 protein, in particular MBNL141 (-ex5+ex7) was significantly
reduced in myoblasts with repeat and even stronger in myotubes. As a result, MBNL143 (+ex5
+ex7) was overrepresented in these cells. Total MBNL2 protein level did not significantly
change upon repeat expansion, but MBNL240 (+ex5+ex8) increased at the expense of
MBNL239 (-ex5-ex8), particularly in myotubes. We therefore conclude that the dysfunction of
MBNL1 and MBNL2 in DM1 consists of a moderate (two to five-fold) reduction in protein
expression, combined with a modified splice variant content, i.e. overrepresentation of pre-
dominantly +ex5 variants. Effects of MBNL protein loss in DM1 have been studied in detail in
vivo in Mbnl knockout mice, which showed that Mbnl1 and Mbnl2 have distinct functions,
predominantly in muscle and brain respectively, but also that the two isoforms can partially
compensate for each other’s absence [3,4,21,22]. Effects of altered splice variant compositions,
but normal total levels, of MBNL1 and MBNL2 protein has not been studied yet, to our best
knowledge.
Alternative splicing determines MBNL1 and MBNL2 localization in the cell, next to effects
on RNA and protein binding, dimerization behaviour and splicing activity [8,10,11,13–16]. In
particular, inclusion of the highly conserved exon 5 has been shown to be responsible for
nuclear localization of MBNL1 [1,2]. Despite preferential inclusion of exon 5 in DM1 cells and
accumulation of this variant in the nucleus, we consistently measured a reduced MBNL1 and,
to a much lesser extent, MBNL2 expression in both the nucleus and the cytoplasm. The decrease
was most prominent in myoblasts carrying the (CTG)2600 repeat, but also evident in the
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corresponding myotubes. A reduced staining in the nucleoplasm of cortical neurons from DM1
patients has been reported earlier [41]. In our muscle cells, irrespective of (CTG)2600 presence,
MBNL1 concentration was highest in the nucleus, while MBNL2 was more or less equally pres-
ent in nucleus and cytoplasm. Importantly, as expected, MBNL staining was concentrated in
foci, but these signals were only a fraction of the total MBNL staining in the nuclei. The differ-
ence in foci number and the relatively large variations in MBNL protein staining in nuclei and
cytoplasm between cells, even in one clonal population, could reflect transcriptional bursts of
DMPK, MBNL1 and MBNL2 [42]. Recently, Wang et al. reported on the involvement of ubiqui-
tination in the subcellular distribution of MBNL1 in neurons [43], but we have not been able to
identify this type of post-translational modification for MBNL1 in our model system.
An important question that remains is how pathogenic DMPK (CUG)n transcripts trigger
the prominent changes in the posttranscriptional regulation of MBNL. Presumably, expanded
(CUG)n RNA-MBNL binding and subsequent formation of foci is the initiating event of the
toxic cascade. After all, the use of antisense oligonucleotides and small molecules that specifi-
cally block this interaction has demonstrated that repeat RNA toxicity effects are reversible
and can be neutralized [44,45]. We assume therefore that (CUG)n RNA-MBNL binding
induces a mechanism that directly or indirectly perturbs MBNL splicing. Whether the number
of MBNL1 and MBNL2 molecules that can be sequestered in foci is sufficient to significantly
reduce the active MBNL concentration in the cell is questionable. However, MBNL1 is known
to stimulate its own exon 5 skipping [46], so an initial small reduction in protein level could in
fact catalyse more robust, sustainable and persistent changes in MBNL1 splicing and protein
variant composition. Alternatively, there might be specific signalling mechanisms that are acti-
vated following (CUG)n RNA-MBNL complex formation and that feed into splicing regula-
tion, but these pathways have not been identified thus far.
In conclusion, we have demonstrated that dysregulation of MBNL1 and MBNL2 in DM1 is
independent of differentiation cues, already occurring in myoblasts, the in vitro equivalent of
muscle progenitor cells to the satellite cells in vivo. Disrupted MBNL expression pertains to
protein level and splice variant composition throughout the entire cell. To obtain further
insight in the exact sequence of events during muscle development, it is important to study
MBNL expression even earlier during embryogenesis, right at the first appearance of toxic
expanded (CUG)n RNA.
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S1 Fig. Subcellular fractionation of proliferating myoblasts and differentiating myotubes
to identify MBNL1 and MBNL2 variants in cytoplasm and nucleus. Western blot analysis of
(A, C) MBNL1 and (B, D) MBNL2 in cytoplasmic (cyto) and nuclear-enriched (nucl) fractions
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tively, to demonstrate enrichment of both fractions. Molecular weights are indicated in kDa.
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of the two usually detected, which represent comigrating protein variants (e.g. Fig 3).
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expanded (CTG)2600 repeat.
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